Expand IOVA Menu
IOVA MENU

IOVA Latest Press Releases

-- December 19, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- November 24, 2025 --

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

-- November 21, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- November 6, 2025 --

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results Globe Newswire 8:00 AM

-- November 3, 2025 --

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Globe Newswire 7:00 AM

-- October 29, 2025 --

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders Globe Newswire 8:15 AM

-- October 23, 2025 --

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 Globe Newswire 4:05 PM

-- October 17, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- October 8, 2025 --

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 3:05 PM

-- September 19, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- August 29, 2025 --

Iovance Biotherapeutics to Present at Upcoming Conferences Globe Newswire 8:30 AM

-- August 22, 2025 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- August 18, 2025 --

Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma Globe Newswire 4:15 PM

-- August 7, 2025 --

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes